CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

and that can turn into enviable share price appreciation in the coming decades. Rachel Warren is a contributing Motley Fool stock market analyst covering pharmaceuticals, biotechnology, medical ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...

The stock of biotechnology firm Intellia Therapeutics has experienced a severe downturn after US regulators imposed a ...

Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that ...

Explore DEFSEC Technologies stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DFSC. Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in ...

Kimberly-Clark Corp. will acquire Tylenol maker Kenvue Inc. in a cash and stock deal valued at almost $49 billion the two companies announced Nov. 3.

Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell ...